Compare Biocon Ltd with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs CADILA HEALTHCARE - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON CADILA HEALTHCARE BIOCON /
CADILA HEALTHCARE
 
P/E (TTM) x 30.2 30.2 99.9% View Chart
P/BV x 3.9 3.6 107.8% View Chart
Dividend Yield % 0.3 1.0 26.5%  

Financials

 BIOCON    CADILA HEALTHCARE
EQUITY SHARE DATA
    BIOCON
Mar-19
CADILA HEALTHCARE
Mar-19
BIOCON /
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs707432 163.6%   
Low Rs554306 180.7%   
Sales per share (Unadj.) Rs91.9128.6 71.5%  
Earnings per share (Unadj.) Rs16.718.5 90.1%  
Cash flow per share (Unadj.) Rs24.224.4 99.1%  
Dividends per share (Unadj.) Rs1.003.50 28.6%  
Dividend yield (eoy) %0.20.9 16.7%  
Book value per share (Unadj.) Rs101.6101.5 100.2%  
Shares outstanding (eoy) m600.001,023.74 58.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.92.9 238.9%   
Avg P/E ratio x37.719.9 189.5%  
P/CF ratio (eoy) x26.115.1 172.3%  
Price / Book Value ratio x6.23.6 170.4%  
Dividend payout %6.018.9 31.7%   
Avg Mkt Cap Rs m378,330378,170 100.0%   
No. of employees `0006.112.4 49.3%   
Total wages/salary Rs m11,65321,241 54.9%   
Avg. sales/employee Rs Th8,994.310,585.0 85.0%   
Avg. wages/employee Rs Th1,900.71,707.8 111.3%   
Avg. net profit/employee Rs Th1,635.31,526.5 107.1%   
INCOME DATA
Net Sales Rs m55,144131,656 41.9%  
Other income Rs m1,4442,011 71.8%   
Total revenues Rs m56,588133,667 42.3%   
Gross profit Rs m15,88329,731 53.4%  
Depreciation Rs m4,4785,986 74.8%   
Interest Rs m7091,935 36.6%   
Profit before tax Rs m12,14023,821 51.0%   
Minority Interest Rs m9469 1.9%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,1235,303 40.0%   
Profit after tax Rs m10,02618,987 52.8%  
Gross profit margin %28.822.6 127.5%  
Effective tax rate %17.522.3 78.6%   
Net profit margin %18.214.4 126.1%  
BALANCE SHEET DATA
Current assets Rs m48,22884,981 56.8%   
Current liabilities Rs m30,37673,425 41.4%   
Net working cap to sales %32.48.8 368.8%  
Current ratio x1.61.2 137.2%  
Inventory Days Days6875 91.6%  
Debtors Days Days86110 78.1%  
Net fixed assets Rs m64,130133,493 48.0%   
Share capital Rs m3,0001,024 293.0%   
"Free" reserves Rs m57,980102,839 56.4%   
Net worth Rs m60,980103,863 58.7%   
Long term debt Rs m15,76639,497 39.9%   
Total assets Rs m121,924234,831 51.9%  
Interest coverage x18.113.3 136.2%   
Debt to equity ratio x0.30.4 68.0%  
Sales to assets ratio x0.50.6 80.7%   
Return on assets %8.88.9 98.8%  
Return on equity %16.418.3 89.9%  
Return on capital %16.818.3 91.6%  
Exports to sales %28.10-   
Imports to sales %18.90-   
Exports (fob) Rs m15,506NA-   
Imports (cif) Rs m10,399NA-   
Fx inflow Rs m15,50648,404 32.0%   
Fx outflow Rs m10,39911,593 89.7%   
Net fx Rs m5,10736,811 13.9%   
CASH FLOW
From Operations Rs m11,54628,823 40.1%  
From Investments Rs m-7,138-57,387 12.4%  
From Financial Activity Rs m-2,41718,846 -12.8%  
Net Cashflow Rs m2,103-7,105 -29.6%  

Share Holding

Indian Promoters % 40.4 74.8 54.0%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 8.3 101.2%  
FIIs % 10.7 5.9 181.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 11.0 180.9%  
Shareholders   109,995 44,069 249.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   NOVARTIS  TORRENT PHARMA  FRESENIUS KABI ONCO.  CIPLA  ABBOTT INDIA  

Compare BIOCON With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 178 Points Higher; Telecom and Power Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest throughout the day today and ended on a positive note.

Related Views on News

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (2QFY20); Net Profit Down 79.3% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)

Jul 2, 2020

In the first of two videos, I'll show you how to identify the best stocks for intraday trading.

Be Prepared to Profit from the Coming Crash in Oil Prices(Fast Profits Daily)

Jun 25, 2020

The stability in crude oil prices will not last much longer. Be ready to make fast profits when the time comes to short crude.

Tata Motors Tripled in 18 Months but You Can Do Even Better. Here's How...(Profit Hunter)

Jun 24, 2020

Rahul is ready for a repeat of his famous 2008 Tata Motors call.

Two Agri Stocks Are Likely to Outperform Even in this Market(Profit Hunter)

Jul 2, 2020

Why we have recommended two agriculture stocks for our Hidden Treasure subscribers. Read on...

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Jul 3, 2020 (Close)

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS